Dr. Zhihong Chi has long been engaged in clinical practice and research in medical oncology. She has extensive experience in systemic therapy, immunotherapy, and management of treatment-related complications for melanoma and genitourinary tumors. She has participated in numerous domestic and international clinical trials and was one of the key investigators in the pivotal registration study that led to the approval of China’s first anti–PD-1 monoclonal antibody, toripalimab.
Dr. Chi received advanced training at Memorial Sloan-Kettering Cancer Center (MSKCC) in the United States. She has received multiple academic awards, including the Second Prize of the Chinese Medical Science and Technology Award, the Second Prize of the Beijing Science and Technology Award, the Second Prize of the Chinese Anti-Cancer Association Science and Technology Award, and the Third Prize of the Hua Xia Medical Science and Technology Award. She has published multiple research articles in leading international journals such as Journal of Clinical Oncology, Clinical Cancer Research, and European Journal of Cancer.
